We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




New Coronary Catheter Tackles Challenging Environments

By HospiMedica International staff writers
Posted on 16 Oct 2014
A novel coronary catheter system features controlled guidewire advancement technology to help cross coronary chronic total occlusions (CTOs).

The ENABLER-C Coronary Catheter system is based on a unique balloon design to provide guidewire support, centralization, and controlled advancement. More...
The system comprises the ENABLER-C catheter, with the look and feel of a traditional balloon catheter; the ENABLER pressure control unit (PCU), used to automate the inflation and deflation of the catheter’s balloon, a syringe-set, and a sterile cover. The catheter is first advanced to the target lesion over a standard 0.035 guidewire; it is then inflated proximal to the target lesion, anchoring the balloon against the vessel wall, resulting in guidewire support and centralization.

Additional inflations of the balloon result in the gripping of the guidewire and balloon elongation, resulting in a controlled advancement forward of the guidewire. A decrease in balloon pressure results in the balloon returning to its original shape, so the guidewire can be released and moved freely. The advantage is that advancement the guidewire from a closer proximity to the lesion prevents buckling and allows for focused force transfer. The ENABLER-C Coronary Catheter System is a product of EndoCross (Yokneam, Israel), and has received the European Community CE marking of approval.

“The ENABLER-C Catheter System uses familiar balloon catheter and guidewire technologies and does not require expensive or complex capital equipment,” said Yaron Eshel, chief operating officer of EndoCross. “Therefore, the system may provide the simplicity and consistency needed to increase the overall rate of PCI treatment of CTOs, resulting in improved patient treatment and lower overall cost.”

“EndoCross has developed a unique chronic occlusion crossing device that can facilitate penetration and crossing of complex occlusions with standard off-the-shelf wires. The device allows for effective and controlled luminal crossing,” added Maurice Buchbinder, MD, chief medical officer of EndoCross.

Coronary Artery Disease (CAD) remains as the leading cause of death in both the European Union and globally. Significant improvements in acute and long-term results drive an ongoing interest in the percutaneous coronary intervention (PCI) treatment of CTOs. However, due to the complexity of existing solutions and a persistent degree of outcome uncertainty, many patients with CTOs are currently referred for more costly coronary artery bypass graft (CABG) surgery, rather than being treated by PCI.

Related Links:

EndoCross



Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Gold Member
12-Channel ECG
CM1200B
New
Ureteral Dilatation Balloon
Dornier Equinox
New
Hospital Data Analytics App
Alarm History Analytics
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: A research collaboration aims to further advance findings in human genomics research in cardiovascular diseases (Photo courtesy of 123RF)

Bayer and Broad Institute Extend Research Collaboration to Develop New Cardiovascular Therapies

A research collaboration will focus on the joint discovery of novel therapeutic approaches based on findings in human genomics research related to cardiovascular diseases. Bayer (Berlin, Germany) and... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.